Congressman Glenn Grothman (R-Glenbeulah) today issued the following statement after President-elect Trump’s press conference, during which the president-elect questioned pharmaceutical companies’ drug prices: “President-elect Trump was right to call out Big Pharma today for high drug prices and manufacturing practices that take place primarily outside of the U.S. My concerns include not only outrageous prices, but also overprescribing of opiates which leads to heroin addiction and overprescribi... Read more

The Hill Mylan CEO Should be Ashamed of EpiPen Prices By Congressman Glenn Grothman (R-Wis.) Last week the House Oversight and Government Reform Committee held a hearing on the skyrocketing price of life-saving Epinephrine Auto-Injectors, better known as the EpiPen. This hearing was especially important because EpiPens are predominantly used to keep children alive, which makes accessibility imperative. During the hearing, I and other members of the committee questioned Heather Bresch, CEO of Myl... Read more

(Washington, D.C.) - Congressman Glenn Grothman (R-Glenbeulah) last night questioned officials about the price of EpiPens at a House Oversight and Government Reform Committee (OGR) hearing. Heather Bresch, CEO of Mylan, the pharmaceuticals company that manufacturers EpiPen, and FDA Deputy Director, Center for Drug Evaluation and Research Dr. Doug Throckmorton addressed the skyrocketing price of the life-saving EpiPen. Dr. Throckmorton also touched on ways to speed up the FDA approval process of ... Read more

(Washington, D.C.) - Rep. Glenn Grothman (R-Wisconsin) released the following statement on the King v. Burwell decision by the Supreme Court to uphold Obamacare subsidies. “The uncertainty working families and employers throughout my district have suffered because of Obamacare is disappointing, to say the least,” said Congressman Grothman. “It is frustrating that once again the Supreme Court has disregarded Congressional intent. This ruling shows us that the rule of law is under attack by not on... Read more